Myconostica Announces Appointment of David Evans as Non-Executive Director

11-Oct-2010 - United Kingdom

Myconostica Ltd announces the immediate appointment of Mr David Evans as independent Non-Executive Director.

As the former CFO of Shield Diagnostics Ltd, David guided the business through its IPO and then, as its CEO, through its merger with Axis Biochemical ASA to form Axis-Shield plc, a Fully Listed diagnostics company. He is currently Chairman or Non-Executive Director of a number of companies within the diagnostic and life science space including Epistem Holdings plc, Immunodiagnostic Systems Holdings plc and Omega Diagnostics Group plc, all AIM listed diagnostic companies. David was Chairman of Manchester-based personalised medicine/ companion diagnostic business DxS Ltd for three years until June 2009 and during this time he steered DxS’s transformation from a reference genetics laboratory to a thriving molecular diagnostics products company.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures